Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 7:50 PM
Ignite Modification Date:
2025-12-24 @ 7:50 PM
NCT ID:
NCT05922904
Brief Summary:
To learn about the effects of brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine when given to patients who have Stage II cHL with bulky mediastinal disease or advanced cHL (Stage III or IV) and who have not received treatment for the disease.
Detailed Description:
Primary Objectives:
● To assess the complete response (CR) rate at the end of therapy (EOT) with Brentuximab vedotin and pembrolizumab, doxorubicin and dacarbazine in subject with previously untreated stage II bulky mediastinal disease or advanced stage cHL.
Secondary Objectives:
* To assess the safety of BvP+AD
* To assess the complete remission rate at interim PET (CR iPET)
* To assess the overall response rate (ORR)
* To assess the duration of response (DOR)
* To assess the duration of complete response (DOCR)
* To assess event-free survival (EFS)
* To assess progression free survival (PFS)
* To assess overall survival (OS)
Study:
NCT05922904
Study Brief:
Protocol Section:
NCT05922904